BIOVAIL, ELAN SETTLE FTC CHARGES OVER MARKETING AGREEMENT FOR GENERIC ADALAT In re Biovail Corp. and Elan Corp. | Secondary Sources | Westlaw

BIOVAIL, ELAN SETTLE FTC CHARGES OVER MARKETING AGREEMENT FOR GENERIC ADALAT In re Biovail Corp. and Elan Corp. | Secondary Sources | Westlaw

View on Westlaw or start a FREE TRIAL today, BIOVAIL, ELAN SETTLE FTC CHARGES OVER MARKETING AGREEMENT FOR GENERIC ADALAT In re Biovail Corp. and Elan Corp., Secondary Sources
10 No. 3 Andrews Health L. Litig. Rep. 16
Andrews Health Law Litigation Reporter
September 13, 2002
Settlement:
Copyright (c) 2002 Andrews Publications

BIOVAIL, ELAN SETTLE FTC CHARGES OVER MARKETING AGREEMENT FOR GENERIC ADALAT

In re Biovail Corp. and Elan Corp.

Biovail Corp. and Elan Corp. have agreed to settle Federal Trade Commission charges that they hampered competition in the U.S. market for a generic version of Bayer AG's hypertension medication Adalat. The FTC said this was the first time it took...
End of Document© 2023 Thomson Reuters. No claim to original U.S. Government Works.